TENAX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.68 USD | +2.51% |
|
-4.91% | -83.25% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.21M |
|---|---|---|---|---|---|
| Net income 2024 * | -16M | Net income 2025 * | -18M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.5
x | P/E ratio 2025 * |
-1.01
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.51% | ||
| 1 week | -4.91% | ||
| Current month | -13.21% | ||
| 1 month | -5.40% | ||
| 3 months | -60.92% | ||
| 6 months | -85.32% | ||
| Current year | -83.25% |
1 week
3.50
3.81
1 month
3.484.25
Current year
3.4822.88
1 year
3.4861.20
3 years
3.483 680.00
5 years
3.485 888.00
10 years
3.48172 160.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 21-07-13 | |
| Director of Finance/CFO | 69 | Jan. 10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 14-04-03 |
June Almenoff
BRD | Director/Board Member | 67 | 21-02-24 |
Declan Doogan
BRD | Director/Board Member | 72 | 21-02-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3.68 | +2.51% | 21,704 |
| 24-04-17 | 3.59 | -0.55% | 25,972 |
| 24-04-16 | 3.61 | +0.14% | 13,622 |
| 24-04-15 | 3.605 | -4.12% | 34,007 |
| 24-04-12 | 3.76 | -2.84% | 22,461 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotes
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Companyâs other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.68
USD
Average target price
32.5
USD
Spread / Average Target
+783.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -83.25% | 7.21M | |
| -1.82% | 41.35B | |
| +42.15% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- TENX Stock
